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INTRODUCTION
Adenosine deaminase (ADA), an enzyme essential for the
differentiation of lymphoid cells, has been used for monitor-
ing several diseases in which immunity has been altered (1).
As an indicator of cellular immunity, the serum activity of this
enzyme has been suggested to be altered in diseases that cause
a cell-mediated immune response such as rheumatoid arthri-
tis, systemic lupus erythematosus, and tuberculosis (2, 3).
ADA catalyses the hydrolytic deamination of adenosine to
inosine and 2’-deoxyadenosine to 2’-deoxyinosine (4, 5). This
enzyme is widely distributed in human tissues, especially in
the lymphoid tissues, and is essential for the maturation and
function of human blood monocytes and macrophages (6, 7).
It has been considered as an indicator of a nonspecific marker
of T-cell activation (8). Human ADA exists in at least three
molecular isoforms, ADA1, ADA2, and ADA1 and ADA-
complexing protein (9). The homeostasis of these isoforms
and the activity of the isoenzymes ADA1 and ADA2 in
human cells are of extreme importance in maintaining the
homeostasis between adenosine and 2’-deoxyadenosine in
monocytes and macrophages (4, 5). There have been several
reports on the increase in serum ADA activity in diseases
where cellular immunity is activated (6). Lymphocytes or the
monocyte-macrophage cell system have been assumed to be
responsible for the changes in serum ADA activity; however,
the precise mechanisms by which serum ADA activity is al-
tered has not been clarified (6, 11).
Normal pregnancy has been associated with depressed cell
immunity (12), and thus, serum ADA activity may play a
significant role (13). There have been conflicting reports about
the changes in the activity of serum ADA in normal preg-
nancy compared to the age-matched non-pregnant women
(14-16). However, to our knowledge, only few studies have
been performed investigating the changes in serum ADA
activity according to gestational age, and the clinical signif-
icance of changes in ADA activity throughout normal preg-
nancy has not been elucidated (14, 15). Several studies have
shown that serum ADA activity is significantly increased in
women with recurrent spontaneous abortions, preeclampsia,
and hyperemesis gravidarum where enhanced cell-mediated
immunity is thought to be an important pathogenesis (17-
19). There have also been reports showing low levels of both
maternal serum and placental ADA activity in anembryonic
pregnancies and missed abortions (20).
In this study, we measured the serum ADA activity in
normal pregnant women and examined the changes of serum
ADA activity according to the gestational age. 
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Changes in Serum Adenosine Deaminase Activity during Normal
Pregnancy
Adenosine deaminase (ADA), an enzyme essential for the differentiation of lymphoid
cells, has been used for monitoring diseases with altered immunity. The purpose of
this study was to investigate the changes in serum ADA activity throughout normal
pregnancy. We measured the catalytic values of serum ADA from 202 normal preg-
nant women using a commercial kit. Subjects were divided into four groups accord-
ing to the gestational age in weeks (Gwks) (Group I: 5-9 Gwks [n=58]; Group II:
15-20 Gwks [n= 63]; Group III: 24-30 Gwks [n=34]; Group IV: 30-39 Gwks [n=47]).
The serum ADA levels for the Groups I, II, III, and IV were as follows: 20.1±6.9
IU/L, 20.0±7.6 IU/L, 37.9±19.9 IU/L, and 24.5±8.6 IU/L, respectively. The serum
ADA activity of group III was significantly higher than the other groups (p<0.05).
However, there was no significant correlation between the Gwks and the serum
ADA activity. Furthermore, other parameters, such as maternal age (p=0.29), ges-
tational age at delivery (p=0.07), delivery mode (p=0.39), and birth weight (p=0.59)
had no correlation with ADA activity. Reference values of serum ADA in normal
pregnancy may provide important database for making clinical decisions in preg-
nancies complicated by conditions where cellular immunity has been altered.
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MATERIALS AND METHODS
Patients who received continuous antenatal care and under-
went either normal spontaneous vaginal delivery or cesarean
section at the Yonsei University Medical Center from January
of 2004 until March of 2006 were recruited for this study.
The criteria for eligibility were as follows: 1) well established
gestational age confirmed by ultrasonography, 2) singleton
fetus, 3) no fetal anomaly, 4) nonsmoker, 5) normal response
to glucose tolerance testing, 6) no evidence of recent infec-
tion, 7) no prescribed medications, and 8) no maternal medical
complications. Each patient was examined monthly in the
outpatient department until the 24th week of gestation, then
bimonthly until the 36th week of gestation and subsequent-
ly weekly until delivery. If the women developed any com-
plications throughout the pregnancy, they were excluded
from the study. All deliveries resulted in live infants with an
1-min Apgar score ≥7 and each infant’s birth weight was
appropriate for gestational age.
Total of 202 women met the inclusion criteria and were
included in this study. All patients gave informed consent
after having been informed that they would not benefit directly
from the measurement of the serum ADA. In order to reduce
the inconvenience to the participants, the blood specimens
were collected when the participants came for their routine
examinations; first-visit laboratory tests (5-10 gestational
weeks), serum -fetoprotein screening (15-20 gestational
weeks), glucose tolerance test (24-28 gestational weeks), and
pre-delivery laboratory tests (30-39 weeks). The study groups
were divided into four groups as follows: Group I-from 5 to
10 gestational weeks (n=58); Group II-from 15-20 gesta-
tional weeks (n=63); Group III-from 24-30 gestational weeks
(n=34); and Group IV: from 30 to 39 gestational weeks (n=47).
The measurements were taken after an overnight fast. Ve-
nous blood specimens were collected and the serum obtained
was stored at -80℃ until further analysis. The activity of the
ADA was assayed using an automatic analyzer (TBA-80FR;
Toshiba, Tokyo, Japan) with a commercial kit according to
the instructions of the manufacturer (Toyobo, Osaka, Japan).
The enzyme activity was determined by quantifying inosine
liberated from the substrate, adenosine (10 mM). Inosine was
converted by purine nucleoside phosphorylase into hypox-
anthine, which was further converted by xanthine oxidase
into uric acid and hydrogen peroxide. The hydrogen perox-
ide was then converted into the quinone dyes by peroxidase,
4-aminoantipyrine, and N-ethyl-N-(2-hydroxy-3-sulfopro-
pyl)-m-toluidine, and the absorbance at 548/700 nm was
measured. The detection limit of the assay was 0-200 IU/L
with intra- and interassay coefficients of variable less than
5% and 10%, respectively. 
Data were shown as Median±SEM (standard error of the
median). Statistical analysis of the results was carried out
using the one-way ANOVA (analysis of variance) for com-
parison between the four groups. Multiple logistic regression
was also performed to evaluate the independent effects of vari-
ables on ADA activity. Differences were considered signifi-
cant at p<0.05.
RESULTS
The clinical description of the participants in this study is
given in Table 1. There was no significant difference among
these four groups in terms of maternal age, parity, gestational
age at delivery, birth weight of the infants, or delivery mode.
All deliveries resulted in live infants with an 1-min Apgar
score ≥7. Each infant’s birth weight was appropriate for ges-
Group I (n=58) Group II (n=63) Group III (n=34) Group IV (n=47)
Maternal age (yr) 29.2±3.4 29.4±2.8 29.9±2.5 29.6±3.8
Gestational age (wks) at study 7.6±3.2 15.8±4.1 26.2±2.6 36.1±3.2
Gestational age (wks) at delivery 39.0±2.2 39.1±3.1 38.9±2.9 39.4±3.1
Parity 0.5±0.2 0.4±0.3 0.3±0.2 0.5±0.3
Birth weight (g) 3,261±723 3,219±897 3,268±567 3,257±891
Delivery mode (%)
Vaginal delivery 75.9 81 73.5 76.7
Cesarean section 24.1 19 26.5 23.3
Table 1. Clinical characteristics of patients in each group
Data represented as mean±STD (standard deviation) value.
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Fig. 1. Changes in serum ADA activity during normal pregnancies.
*p<0.05 vs. Group I, II, and IV. Data represent median±standard
error of median.
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tational age.
Changes in the serum ADA activities are shown in Fig. 1.
The median serum ADA levels in the Groups I, II, III and
IV were as follows; 20.1±6.9 IU/ L, 20.0±7.6 IU/L, 37.9
±19.9 IU/L, and 24.5±8.6 IU/L, respectively. The median
serum ADA activity of Group III (24-30 gestational weeks)
was significantly (p<0.05) higher than those of Groups I, II
and IV. There was no significant correlation between the
serum ADA activity and other measured variables such as
maternal age (p=0.29), gestational age at delivery (p=0.07),
delivery mode (p=0.39), and birth weight (p=0.59).
DISCUSSION
ADA is an essential enzyme for the differentiation of lym-
phoid cells, and changes in ADA activity reflect alteration in
immunity (6-8). However, to have a clear diagnostic signifi-
cance in infectious diseases, the value of ADA activity should
be at least 2.5 times the normal value (21). Alterations in
the serum ADA activity during pregnancy are likely to reflect,
at least in part, changes in the immunological status that
occurs throughout normal pregnancy (12). However, to our
current knowledge, there have only been few reports pro-
viding the reference values of serum ADA activity through-
out normal pregnancy (14, 15).
Yoneyama et al. have measured serum activities of total
ADA, ADA1, and ADA2 in normal pregnant women in
the third trimester and age-matched healthy nonpregnant
women (16). In normal pregnant women, serum total ADA
and ADA2 activities were lower than those of the nonpreg-
nant women, while there was no difference in ADA1 activi-
ty. These results suggest that reduced serum total ADA activi-
ty reflects decreased ADA2 activity, which may be in part
associated with depressed cell-mediated immunity during
normal pregnancy (16). One possible explanation for decreased
ADA activity in normal pregnancy is due to the increase in
pregnancy-related hormones such as estradiol and cortisol
which tends to inhibit ADA activity (22). Another possible
reason is the deamination of adenosine to inosine by ADA,
which favors increased adenosine levels (23). Adenosine in
turn exhibits inhibitory effect in platelet activation during
pregnancy (24). Thus, the observed elevation of adenosine
and decreased ADA activity in late normal pregnancy may be
thought to be a compensatory mechanism that tends to main-
tain the vascular integrity to increase the uterine and placen-
tal blood flow.
On the contrary, in pregnancies complicated by preeclamp-
sia which is characterized by enhanced cell-mediated immu-
nity (25), ADA activities of both the maternal serum and
fetal cord blood were increased (18, 26). An increase in ADA
activity in preeclampsia may indirectly contribute to the
maintenance of immune response in preeclampsia by con-
trolling adenosine levels. Another study demonstrated an
increase in serum total ADA and ADA2 activities in women
with hyperemesis gravidarum, which was accompanied by
high lymphocyte and monocyte counts (19). The clinical
significance and the regulatory mechanism of the increased
ADA activity in complicated pregnancies with altered cellu-
lar immunity remain to be elucidated. 
In the present study, no significant correlation was shown
between the serum ADA activity and gestational age in nor-
mal pregnant women. Serum ADA activity of Group III was
significantly higher than the other three groups, which is
somewhat different from an earlier study that showed that
serum ADA values did not differ among each trimester of
pregnancy (15); however, the study population differed from
that of the present study, which may account for the discrep-
ancy in the results. The significant increase in ADA activity
seen in our study during 24 to 30 gestational weeks may be
associated with the fact that the increase in maternal cardiac
output reaches its peak during the late second trimester to
early third trimester and decreases in late pregnancy (27).
Moreover, maternal blood volume expands most rapidly dur-
ing the late second trimester (28). The major source of cir-
culating adenosine in the bloodstream is the platelet, vascu-
lar endothelium, and red blood cells (29). We can postulate
that the rapid increase in red blood cells and vascular endo-
thelium during the late second to early third trimester may
release adenosine into the bloodstream, elevate the concen-
tration, and thereby exert its vasodilator actions to increase
blood supply to the uterine and placental unit. Thus, the
activity of ADA may increase in order to degrade the ele-
vated adenosine and to maintain the level of adenosine at its
kinetic equilibrium. However, the clinical significance of
the increase in serum ADA in Group III is not fully under-
stood, and further studies are needed to elucidate the possi-
ble mechanisms involved.
A number of limitations of the present study should be
noted. First, instead of dividing the participants into four
different groups according to the gestational age, the serum
ADA activity should be prospectively measured from the
same set of normal pregnant women from early 1st trimester
to delivery. Second, to our knowledge, we have not found
any studies in the literature reporting the changes in the
activities of ADA and its isoforms throughout the normal
pregnancy. Thus, it would be interesting to see if the change
in the serum ADA activity is accompanied by similar changes
in ADA isoforms, especially ADA2. Despite the limitations
of the this study, we were able to provide serum ADA values
throughout normal pregnancy from early first trimester to
third trimester which was different from previous studies that
only compared the serum ADA activity of pregnant women
in their third trimester to the non-pregnant controls (16).
We conclude that serum ADA activity may be a marker
of altered cell-mediated immunity in pregnancy, and the sig-
nificance of the regulatory mechanisms that alter the activi-
ty of serum ADA and its isoenzymes need further studies.
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Reference values of serum ADA in normal pregnancy may
provide important database for making clinical decisions in
high-risk pregnancies where cellular immunity has been
altered.
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